COREY S GOODMAN
CIK 1278411 · Senior Vice President · last filed 2026-02-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.33M
Companies
7
Total Filings
45
Lifetime Open-Market Net
$38.83M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALXO | Director | 113,287 | $1.99 | $225.4K | $21.15M | 9 | 2026-02-04 |
| Ventyx Biosciences, Inc. (VTYX) Delisted | 10%+ Owner | — | $13.99 | — | $0 | 1 | 2022-06-10 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | 10%+ Owner | 2,514,415 | $10.50 | $26.40M | -$14.36M | 2 | 2022-05-09 |
| IPI Legacy Liquidation Co (IMPL) Delisted | 10%+ Owner | 2,309,791 | $0.24 | $556.9K | $33.75M | 1 | 2021-04-29 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 3,940,534 | $54.65 | $215.35M | -$1.72M | 1 | 2020-01-03 |
| PFE | Senior Vice President | 83,327 | $25.25 | $2.10M | $0 | 27 | 2009-05-01 |
| RENOVIS INC (RNVS) Delisted | President and CEO | 558,218 | — | — | $0 | 3 | 2008-02-12 |
Recent Filings · Page 2 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-29 | IPI Legacy Liquidation Co (IMPL) Delisted | Mixed | +13,798,955 | $33.75M | EDGAR |
| 2020-07-21 | ALXO | Mixed | +8,038,585 | $16.15M | EDGAR |
| 2020-07-17 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2020-01-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −71,620 | -$1.72M | EDGAR |
| 2009-05-01 | PFE | Grant (A) | — | $0 | EDGAR |
| 2009-04-16 | PFE | Grant (A) | — | $0 | EDGAR |
| 2009-04-01 | PFE | Grant (A) | — | $0 | EDGAR |
| 2009-03-16 | PFE | Grant (A) | — | $0 | EDGAR |
| 2009-03-02 | PFE | Grant (A) | +51,865 | $0 | EDGAR |
| 2009-01-05 | PFE | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.